<DOC>
	<DOCNO>NCT02536391</DOCNO>
	<brief_summary>This Phase I , open-label , randomize , 3-period crossover study design determine relative bioavailability ipatasertib administer capsule tablet formulation healthy volunteer . In addition , influence food ipatasertib exposure also determine . Participants randomize one six treatment sequence receive three treatment single oral administration ipatasertib , 1 ) tablet formulation fast state , 2 ) capsule formulation fast state 3 ) tablet formulation feed state . Pharmacokinetics assess , standard physical clinical evaluation perform throughout study . Time study expect 3 week .</brief_summary>
	<brief_title>Ipatasertib ( GDC-0068 ) Study Evaluate Formulation Change Food Effect Bioavailability Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female , 18 55 year age , inclusive Body mass index 18.5 29.9 kg/m^2 , inclusive Clinically significant finding medical history screening evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>